Humboldt Fund

?? ?? I am deeply honored to share that Advanced Research Projects Agency for Health (ARPA-H) has awarded Cellino up to $25 million in funding to develop, Nebula, an ultra-scalable, autonomous, cassette-based advanced biomanufacturing technology for personalized regenerative medicines. Cellino’s Nebula project is the first project funded by the Scalable Solutions Mission Office under the ARPA-H Open Broad Agency Announcement. ?????? Thank you to my brilliant team, Matthias Wagner and Abhijit Kulkarni, for driving this effort forward. A heartfelt thank you to Darshak Sanghavi, our program manager, for the incredible alignment and the rest of the ARPA-H team for being amazing partners in this journey. Special thanks to Renee Wegrzyn and Jason R. for your leadership and commitment to ensuring “we can scale manufacturing right alongside other regenerative health innovations.”? ?????? We look forward to democratizing access to autologous induced pluripotent cells via Nebula to build a thriving bioeconomy for cells, tissues, and, ultimately, organs that can be custom-generated for patients everywhere!?Let's go!!!! ?? ?? ?? ?? From ARPA-H’s press release: “The autonomous process represents ARPA-H’s first investment in boosting domestic production capability and capacity of cellular therapies.” https://lnkd.in/eMma_XMp From Cellino’s press release: “Cellino’s proprietary biomanufacturing technology automates traditionally manual, artisanal processes using an AI-guided, laser-based cell management process to reduce variability and increase the consistency of biomanufactured cell and tissue products. Cellino’s proprietary optical bioprocess will drive a meaningful cost reduction for personalized regenerative medicine biomanufacturing using patient-specific closed cassettes. This effort aligns with ARPA-H’s mission to improve health outcomes for everyone.” https://lnkd.in/e795v3ZV #Biomanufacturing #AI #MachineLearning #RegenerativeMedicine #Biotech #Innovation #YourCellsYourCure

Great news from Metagenomi! The company recently announced preclinical data showing durable Factor VIII (FVIII) activity levels through twelve months in its lead hemophilia A program. This exciting development demonstrates the potential for a one-time, curative treatment for hemophilia A, marking a significant advancement in gene editing and precision medicine. This milestone is a testament to Metagenomi’s cutting-edge platform, and we’re eager to see the continued progress as they move toward clinical trials. More info at: https://lnkd.in/g3XAnmgQ #biotech #innovation #geneediting #hemophilia #precisionmedicine #Metagenomi

We’re excited to share that HAYA Therapeutics, an early investment of Humboldt Fund, has entered into a major collaboration with Eli Lilly and Company worth up to $1 billion in biobucks. This partnership focuses on unlocking the potential of the “dark genome” to develop treatments for obesity and metabolic conditions. Congratulations to Haya and Eli Lilly on this exciting milestone! We look forward to seeing the impact of this groundbreaking collaboration. #biotech #innovation #investment #obesityresearch #HumboldtFund #HayaTherapeutics #EliLilly // Samir Ounzain // Daniel Blessing More info at: https://lnkd.in/gX25EfTU https://lnkd.in/ghqfQ_cU

We are thrilled to announce a multi-year collaboration with Eli Lilly and Company to discover novel regulatory genome targets for obesity & related metabolic conditions. The total deal aggregates $1 billion in pre-clinical, clinical and commercial milestone payments, as well as royalties on product sales. "This partnership with Lilly demonstrates the significant advances we have made with our revolutionary regulatory genome RNA-guided platform and validates the potential of targeting lncRNA for chronic conditions. We look forward to working closely with Lilly, an established leader in developing treatments for metabolic diseases, to help bring patients novel disease-modifying therapeutics that could offer greater efficacy, safety and accessibility than currently available treatments" – Samir Ounzain Co-Founder and CEO. Read more about this collaboration in our latest Press Release: https://lnkd.in/eGDSiHHd #Collaboration #Obesity #MetabolicConditions #lncRNA #RegulatoryGenome #HAYATherapeutics

We’re heading to #Chicago for the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting. Chat with our team in Hall A during our poster presentation to learn more about our Phase 1 #ClinicalTrial targeting #KRAS G12V in #solidtumors: https://bit.ly/3wQtBFI #ASCO24?

Attending #ASCO2024 next week? Connect with our team - CEO, Jak Knowles, CSO, Lo?c VINCENT, and CMO, Dirk Nagorsen – to learn more about updates on our work to develop #KRAS-targeting precision #immunotherapies for patients with #solidtumors. American Society of Clinical Oncology (ASCO)

Why compromise? As the #synbio industry advances, new methods for reliable synthesis of more complex DNA constructs are needed. Join Ansa CEO Jason T. Gammack as he describes how #Ansamers will drive the next wave of innovation. Expand Your Design Space: Ask Bigger Questions with Complex DNA Synthesis Service ??Main Stage ??? Tuesday, May 7 ? 12:05 pm PDT #DNAsynthesis #longDNA #biotech #synbio #SyntheticDNA #DNAInnovation #complexDNA #customDNA? #SynBioBeta2024 #AnsamerAnswers

I am honored and humbled to share that I've been named the UCSF Graduate Division Alumni Association Distinguished Alum of the Year 2024! ?????? This recognition is incredibly meaningful to me, and I'm so grateful to everyone who has supported me along this journey. Whether you're a mentor, colleague, friend, or family member, your encouragement has always played a fundamental role in my success. A special thank you to Drs. Bill Rutter, Peter Walter, and Pablo Valenzuela, who have been instrumental in my career development and have inspired me to push the boundaries in our shared love for science and its translation. I’m excited to continue contributing to the advancement of life sciences and look forward to sharing more about the journey ahead. Thank you to the University of California, San Francisco, Graduate Division Alumni Association for this honor, and congratulations to all the other outstanding alumni who have been recognized this year! (Highlights: 0:37–0:48 & 3:13–4:52)

Ansa Biotechnologies’ novel and powerful DNA synthesis approach will soon redefine the DNA synthesis landscape and open the door to new sustainable solutions across various industries. As the company’s new CEO, I’m looking forward to working with this talented team of employees, investors, and collaborators as we empower more researchers with the ability to unlock the next wave of scientific breakthroughs.